Key result
Carriers of both CYP2C9 and VKORC1 polymorphisms had an increased risk of severe overanticoagulation compared with subjects with no or one polymorphism (HR 3.83; 95% CI 1.62-9.05).
Why the study?
Does the combination of VKORC1 and CYP2C9 polymorphisms increase the risk of severe overanticoagulation in patients starting acenocoumarol?
Cohort (n=231)
Yes
Does the combination of VKORC1 and CYP2C9 polymorphisms increase the risk of severe overanticoagulation in patients starting acenocoumarol?
Effect estimate: HR 3.83 (95% CI 1.62-9.05)
Carrying a combination of VKORC1 and CYP2C9 polymorphisms significantly increases the risk of severe overanticoagulation during the initial phase of acenocoumarol treatment.
No takes yet. Share an insight, caveat, or question.
Dual carriers may need intensified INR monitoring on acenocoumarol initiation; leaves open whether genotyping improves outcomes.
Schalekamp et al. (2006) conducted a cohort in acenocoumarol anticoagulation (n=231). Combination of CYP2C9 and VKORC1 polymorphisms vs. No polymorphism or only 1 polymorphism was evaluated on severe overanticoagulation (HR 3.83, 95% CI 1.62-9.05). Carriers of both CYP2C9 and VKORC1 polymorphisms had an increased risk of severe overanticoagulation compared with subjects with no or one polymorphism (HR 3.83; 95% CI 1.62-9.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: